Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8545561 | 1.00 | MAPT (0.40) | MAPTGAAALDH1A1RAB9ASOAT1 | |
| SCHEMBL30999026 | 0.93 | ALDH1A1 (0.38) | MAPTGAAALDH1A1RAB9AMEN1 | |
| SCHEMBL1126496 | 0.89 | TSHR (0.37) | MAPTGAAALDH1A1RAB9AKMT2A | |
| SCHEMBL30420160 | 0.84 | ALDH1A1 (0.40) | MAPTGAAALDH1A1RAB9ASOAT1 | |
| SCHEMBL22213865 | 0.84 | ALDH1A1 (0.40) | MAPTGAAALDH1A1RAB9ASOAT1 | |
| SCHEMBL6642281 | 0.80 | MAPT (0.47) | MAPTGAAALDH1A1RAB9ASOAT1 | |
| SCHEMBL2914885 | 0.80 | ALDH1A1 (0.46) | MAPTGAAALDH1A1SOAT1MEN1 | |
| SCHEMBL16399413 | 0.79 | CES2 (0.31) | ALDH1A1 | |
| SCHEMBL16399415 | 0.79 | CES2 (0.31) | ALDH1A1 | |
| SCHEMBL10950450 | 0.77 | ALDH1A1 (0.43) | MAPTGAAALDH1A1RAB9ASOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250079-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| US-20230250079-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| US-20230250079-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| CN-116209664-A | Small molecule modulators of IL-17 | 利奥制药有限公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-4168114-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO Pharma A/S (DK) | 2023-04-26 | — | — | EP | disclosed |
| US-20220073526-A1 | IL-17A INHIBITORS | ELI LILLY AND COMPANY | 2022-03-10 | — | — | US | disclosed |
| WO-2021250194-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2021-12-16 | — | — | WO | disclosed |
| WO-2020146194-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-07-16 | — | — | WO | disclosed |
| EP-0514198-B1 | 1H-Imidazol-1-yl-methyl benzofuran derivatives with the imidazolyl moiety being substituted by a cycloalkyl group | GLAXO GROUP LTD (GB) | 1998-08-05 | — | — | EP | disclosed |
| US-5498722-A | HYPOTENSIVES | GLAXO GROUP (GB) | 1996-03-12 | — | — | US | disclosed |
| US-5332831-A | Angiotensin antagonist | GLAXO GROUP LIMITED (GB) | 1994-07-26 | — | — | US | disclosed |
| WO-1992020674-A1 | 1H-IMIDAZOL-1-YL-METHYL BENZOFURAN DERIVATIVES, WITH THE IMIDAZOLYL MOIETY BEING SUBSTITUTED BY A CYCLOALKYL GROUP | GLAXO GROUP LIMITED (GB) | 1992-11-26 | — | — | WO | disclosed |
| EP-0514198-A1 | 1H-Imidazol-1-yl-methyl benzofuran derivatives with the imidazolyl moiety being substituted by a cycloalkyl group | GLAXO GROUP LIMITED (GB) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250079-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL2, IL23R | MAPT 521/4885GAA 920/4885ALDH1A1 490/4885 |
| US-20220073526-A1 | IL-17A INHIBITORS | IL17A, IL2, IL15 | MAPT 679/4885GAA 3377/4885ALDH1A1 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.